How does this company make money?
The company charges oncology centres and hospitals for each vial of Keytruda, priced by the milligram dose the patient receives. It also sells Gardasil vaccine doses to healthcare providers and to government vaccination programmes that buy in bulk. Januvia diabetes tablets move through pharmaceutical distributors and end up on retail pharmacy shelves, where each prescription filled generates revenue.
What makes this company hard to replace?
Switching a cancer patient from Keytruda to a biosimilar pembrolizumab is not a simple substitution — the FDA requires bioequivalence studies before oncologists can make that change. Hospital formulary committees must separately revalidate their purchasing contracts and rewrite clinical protocols whenever they bring in a new PD-1 inhibitor supplier. For Gardasil, switching to a different HPV vaccine requires state health department approval, which adds another layer of process that slows any move away from the current product.
What limits this company?
The number of batches Rahway can run sets the ceiling on how much Keytruda the world can get. Hospitals and cancer centres already want more than the plant can produce. Adding more bioreactor capacity is not simply a matter of spending money — each new tank must go through its own multi-year FDA validation process before a single dose from it can be sold. That regulatory clock, not factory floor space or funding, is what caps growth.
What does this company depend on?
The company cannot run without four things: the Chinese Hamster Ovary cell lines that are the biological source of Keytruda; the FDA biologics licence tied to the Rahway facility that permits manufacturing; recombinant yeast strains used to produce its Gardasil HPV vaccine; active pharmaceutical ingredient suppliers that provide the inputs for its Januvia diabetes tablets; and the cold-chain distribution networks that keep temperature-sensitive biologics from degrading before they reach patients.
Who depends on this company?
Oncology treatment centres rely on a steady supply of pembrolizumab to run immunotherapy programmes for melanoma and lung cancer patients — a disruption would leave those patients without their treatment protocol. Pediatric vaccination programmes depend on the company's nonavalent HPV vaccine, Gardasil, to prevent cervical cancer; losing access would leave those programmes without a substitute. Veterinary clinics use the company's Nuflor antibiotic to treat respiratory disease in livestock, and that supply would disappear too.
How does this company scale?
Adding new approved cancer types to Keytruda's label is relatively cheap — it uses the manufacturing capacity already in place at Rahway and requires a regulatory submission rather than a new factory. What does not scale easily is the manufacturing itself. Every additional bioreactor train requires a multi-year FDA validation cycle and cannot be handed off to a third party without losing control over the precise quality standards the molecule demands. So the label portfolio can grow faster than the production base can.
What external forces can significantly affect this company?
The Inflation Reduction Act gave Medicare the authority to negotiate drug prices directly, and Keytruda — as the highest-spend drug in the programme — is a primary target, which puts direct downward pressure on what the company can charge. The European Medicines Agency has biosimilar approval pathways that will open pembrolizumab competition in European markets after the 2028 patent expiry. In China, regulators require companies to run separate local clinical trials before granting market access, which delays and adds cost to entering what is one of the largest oncology markets in the world.
Where is this company structurally vulnerable?
The composition-of-matter patent on pembrolizumab expires around 2028. After that, the FDA can approve biosimilar versions made by other manufacturers. Once hospital formulary committees complete the required bioequivalence reviews and rewrite their purchasing contracts, competing suppliers will be able to sell the same molecule for the same approved cancer types. That removes the pricing power the company currently holds, because the clinical case for the drug has already been proven in public trials that every competitor can point to.
CompanyGraph